Shachar Peles, MD
Medical Oncology · Palm Springs, FLNPI 1568412930
Payments from drug & device makers
Across 2,152 payments — averaging $1810.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$933K
- Genentech, Inc.$502K
- AbbVie$435K
- Bristol Myers Squibb$416K
- Novartis$339K
- Karyopharm Therapeutics Inc.$281K
- plus $990K from 54 others
Across 3 payments — averaging $2007.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$11,7889%
- Speaking & faculty fees$90,94869%
- Travel & lodging$6,1265%
- Food & beverage$23,04217%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,896,180 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 197 | $3,342,508 |
| JakafiRuxolitinib Phosphate | 88 | $1,256,304 |
| XtandiEnzalutamide | 82 | $1,079,017 |
| PomalystPomalidomide | 27 | $615,600 |
| XpovioSelinexor | 18 | $555,293 |
| CalquenceAcalabrutinib Maleate | 39 | $532,352 |
| TibsovoIvosidenib | 12 | $376,249 |
| NinlaroIxazomib Citrate | 28 | $343,499 |
| NubeqaDarolutamide | 29 | $330,114 |
| ImbruvicaIbrutinib | 20 | $324,062 |
| TagrissoOsimertinib Mesylate | 20 | $307,354 |
| Lenalidomide | 23 | $269,009 |
| VerzenioAbemaciclib | 13 | $196,269 |
| TasignaNilotinib Hcl | 12 | $116,891 |
| XareltoRivaroxaban | 106 | $105,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $415,845 | $3,342,508197 claims |
| Incyte CorporationJakafi | $843 | $1,256,30488 claims |
| Astellas Pharma US IncXtandi | $347 | $1,079,01782 claims |
| AstraZenecaCalquence, Tagrisso | $34,710 | $839,70659 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $81,992 | $615,60027 claims |
| Karyopharm Therapeutics Inc.Xpovio | $280,561 | $555,29318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $36,072 | $343,49928 claims |
| BayerNubeqa | $409 | $330,11429 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $26,688 | $324,06220 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $228 | $196,43025 claims |
| NovartisTasigna | $338,979 | $116,89112 claims |
| Johnson & JohnsonXarelto | $23,151 | $105,549106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Palm Springs
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.